RE:RE:RE:RE:RE:RE:AA and mBCNoteable, in which subset of HR+ HER- mBC treatment situations are you saying paclitaxel is the SOC? My research shows nowadays it's used mainly when patients have progressed after CDK4/6 inhibitor treatment, or in the 20% of patients who don't respond to CDK4/6. This would imply that CDK4/6 is the SOC.
As I recall, the BRACELET-1 PFS numbers reported at ASCO were roughly equal to those exhibited in CDK4/6 treatments. Problem is, most mBC patients eventually develop resistance to CDK4/6 and have to transition to other treatments.